Seasonal Influenza Vaccine Effectiveness among Children Aged 6 to 59 Months in Southern China by Yang, Zhicong et al.
Seasonal Influenza Vaccine Effectiveness among
Children Aged 6 to 59 Months in Southern China
Zhicong Yang*, Zhiqiang Dong, Chuanxi Fu*
Guangzhou Center for Disease Control and Prevention, Guangzhou, China
Abstract
In China the protective effect of seasonal influenza vaccine has only been assessed in controlled clinical trials and proven to
be highly effective. However, the post-licensure effectiveness of influenza vaccine has not been examined. In our study all
influenza cases from the 19 surveillance sites in Guangzhou were laboratory confirmed during 2009 and 2010. Controls were
randomly selected from children aged 6 to 59 months in the Children’s Expanded Programmed Immunization
Administrative Computerized System. 2529 cases and 4539 controls were finally enrolled. After adjusting for gender, age
and area of residence, the vaccine effectiveness of full vaccination was 51.79% and 57.78% in the 2009 and 2010 influenza
season, respectively. Partial vaccination provided 39.38% and 35.98% protection to children aged 24 to 59 months in 2009
and 2010, respectively, and no protective effect was observed among younger children. Full vaccination is highly protective
and partial vaccination is protective for older children. Influenza vaccination in general should be encouraged, and full
vaccination should be particularly encouraged because its protective effect is much stronger than that of partial vaccination.
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Introduction
Influenza causes more morbidity than any other vaccine-
preventable illness [1] and leads to an estimated 0.7 to 0.9
hospitalizations, 50 to 95 outpatients visits, 6 to 27 emergency
department visits, and 30 to 90 courses of antibiotics each year per
1000 children aged less than 5 years [2,3,4]. Rates of influenza-
related hospitalizations, acute otitis media, and pneumonia are
particularly high in children younger than 2 years of age
[2,4,5,6,7]. Immunization is the major public health measure for
the prevention of influenza virus infection. Because the predom-
inant circulating strains of the influenza virus drift over time,
influenza vaccination is recommended each year.
On the Tropic of Cancer, with over 7.94 million registered
inhabitants and a floating population of 4.76 million, Guangzhou
is the largest trading city in southern China. Routine influenza
virus surveillance data show that in Guangzhou, the influenza
season peaks from March to July, and seasonal influenza vaccine
usually becomes available before October [8]. Since the Severe
Acute Respiratory Syndromes (SARS) epidemic in China in 2003,
the population’s awareness of influenza vaccination has greatly
improved and more influenza vaccinations were administered in
2003 than ever before. According to the Vaccine Management
System in Guangzhou Center for Disease Control and Prevention
(GZCDC), which dispatches vaccines to all hospitals and health
communities in the city, there were 11286, 58570, 84948 and
390138 vaccinations administered from 2000 to 2003, respectively.
From 2009 to 2010, there were 603,557 doses of influenza vaccine
for children used in Guangzhou, among which 51.2% (308,524
doses) were from Pasteur, 30.3% (182,804 doses) were from
GlaxoSmithKline, 16.5%(99,821 doses) were subunit vaccines,
and only 2.1% (12,408 doses) were from domestic manufacturers
(Figure 1).
In China, the protective effect of seasonal influenza vaccine has
only been assessed in controlled clinical trials (seroconversion
reports) and has been proven to be highly effective [9,10,11].
However, the post-licensure effectiveness of influenza vaccine has
not been examined. In this study, we aimed to estimate the vaccine
effectiveness (VE) of trivalent inactivated influenza vaccine among
children by using a case-control design.
Materials and Methods
Study subjects
Nineteen hospitals or health communities located in all 12
districts of Guangzhou City were required to report weekly to
GZCDC the total number of consultations and any patients
presenting with influenza-like illness (ILI), which was defined as a
history of body temperature $38uC accompanying with cough or
sore throat symptoms (National Influenza Surveillance Plan, 2010,
China’s Ministry of Health). After the informed consent was
signed, participating general practitioners collected data on
patients’ birth date, gender, and area of residence. We restricted
patients in our study to those aged 6 to 59 months. Nose and
throat swabs were offered to patients presenting within 3 days of
the onset of symptoms. Influenza like illness meeting our case
definition reporting to 19 surveillance sites in Guangzhou were
subjected to laboratory testing. The presence of influenza virus in
the swab samples was detected by by real-time polymerase chain
reaction (RT-PCR) and/or isolation of the virus in cell cultures, as
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RNA of influenza virus, including seasonal H1N1, H3N2 and B;
or ii) isolation of the virus.
Controls were randomly selected from children aged 6 to 59
months in the Children’s Expanded Programmed Immunization
(EPI) Administrative Computerized System as described previous-
ly [13]. Controls did not have ILI during the study influenza
season, which was confirmed by a phone call by physicians from
GZCDC.
Influenza vaccination status
Influenza vaccination information was retrieved from the
computerized system mentioned above, in which the reporting
of vaccines administered to children less than 6 years in
Guangzhou was required. Influenza vaccination status was
classified as fully vaccinated, partially vaccinated or unvaccinated,
according to the national guidelines for each season. Children
were considered to be fully vaccinated if they received 2 doses of
vaccine at least 28 days apart during the influenza season under
study, with the second dose given at least 14 days before ILI onset,
or at least 1 dose in a previous influenza season and 1 dose in the
season under study, administered at least 14 days before ILI onset.
Children were considered to be partially vaccinated if they
received only 1 of 2 vaccine doses during the current season, and
the dose was received at least 14 days before ILI onset, or if 2 doses
were received during the current season with the second dose
administered within 14 days before ILI onset or less than 28 days
after the first dose. Children were considered to be unvaccinated if
they were not vaccinated in the study season or if they received the
first of 2 doses within 14 days before ILI onset.
Statistical analysis
We restricted our analysis to patients who presented for medical
attention at any of the 19 sentinel surveillance sites and who
subsequently had a swab taken for the identification of influenza
virus. Data were colleted and aggregated at GZCDC. Exclusion
criteria for cases and controls included absence of records in the
Children EPI Administrative Computerized System.
Data analysis was conducted using SPSS statistical software
(version 13.0, SPSS, Inc., Chicago, IL). We used x
2 and t test
analyses to compare the characteristics of each group. VE was
calculated as one minus the adjusted matched odds ratio
(OR)6100%, where the OR was the odds of confirmed influenza
among the vaccinated compared with the odds of influenza among
the unvaccinated. For all analyses, P values not more than 0.05
were regarded as significant.
The protocol of this study was approved by the ethics committee
of GZCDC and written informed consent was obtained from the
guardians of all children recruited to undergo a swab test.
Results
Based on the Children’s EPI Administrative Computerized
System, we identified 1,806 cases (81.2% of total 2,225) and 2,400
controls in 2009, yielding 4,206 total subjects in 2009, and 723
cases (86.7% of total 834) and 2139 controls in 2010, yielding
2,862 total subjects in 2010. Demographic information, such as
gender, age and area of residence, was similar between cases and
controls. Roughly 12% of cases had received full or partial
influenza vaccination before their disease onsets (Table 1).
The overall vaccine effectiveness of full vaccination compared to
no vaccination was 46.57% [95% confidence interval (CI), 35.30–
55.89] and 56.20% (95% CI, 41.78–67.04) among children in the
2009 and 2010 influenza seasons, respectively. After adjusting for
gender, age and area of residence, the VE of full vaccination was
51.79% and 57.78% in the 2009 and 2010 influenza seasons
(p,0.001), respectively.
Partial vaccination provided weaker protection than full vaccina-
tion. Partial vaccination provided 39.38% and 35.98% protection to
children aged 24 to 59 months in 2009 and 2010, respectively, and no
protective effect was observed among younger children.
The VE of full vaccination against influenza virus A was
50.91% (95% CI, 39.39–60.23) and 17.28% (95% CI, 226.06 to
45.72) against influenza virus B in 2009. In 2010, the VE against
influenza virus A and B was 57.72% (95% CI, 32.01–73.71) and
56.71% (95% CI, 34.16–71.53), respectively. Our viral surveil-
lance data (unpublished) showed that in Guangzhou, the influenza
virus constituent ratios for A (H1N1, H3N2) and B subtypes in
2009 were 73.24% and 26.76%, respectively, based on 3,481
swabs. The ratios in 2010 were 42.02% and 57.98%, respectively,
based on 2,689 swabs. However, due to a lack of further
information, we cannot determine how well the circulating and
vaccine strains of influenza matched.
Figure 1. Seasonal influenza vaccine use in Guangzhou during 2009 and 2010.
doi:10.1371/journal.pone.0030424.g001
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We analyzed vaccination information for 2,529 laboratory-
confirmed influenza cases and 4,539 controls from 2009 to 2010.
We discovered that the VE for full vaccination versus no
vaccination was 51.79% in the 2009 influenza season and
57.78% in the 2010 influenza season (p,0.001). This post-
licensing study of VE found full vaccination to be highly protective
and partial vaccination to be protective of children aged 24 to 59
months.
The effectiveness of seasonal influenza vaccine over multiple
influenza seasons, especially against laboratory-confirmed influen-
za, in children younger than 5 years of age has not been well
studied. Over the ten years that the vaccine has been used in
China, VE has not been reported. Our study, which used a large
sample size, is the first to determine the VE of seasonal influenza
vaccine in China. In China, many controlled clinical studies on
influenza vaccine seroconversion have shown that different
seasonal influenza vaccines have similar immunogenicity to three
sub-types of influenza virus (H1N1, H3N2 and B) [9,10,11].
Pre-licensing studies normally evaluate protection under the
optimal conditions of clinical trials. However, the real contribution
of a vaccine is better estimated by its performance when used in
practice. Efficacy figures from clinical trials cannot easily be
converted to VE because during routine practice, not all
susceptible children will be immunized before exposure or receive
a full immunization program. In addition, the population of
vaccine recipients in practice typically expands beyond the
healthy, highly responsive groups that are usually selected for
efficacy trials [13,14,15,16]. Therefore, from a public health
perspective, the impact of vaccination on practical outcomes
should be analyzed.
Because there is no pre-licensing study available on influenza
vaccine efficacy against confirmed influenza cases, we find it
difficult to compare our results with those of previous studies. Bian
GL et al. employed a face-to-face interview and a self-administered
questionnaire to acquire the incidence of ILI among 470 healthy
persons aged 0 to 17 years in Ningbo, China, from December
2002 to September 2003, and found that one dose of seasonal
influenza vaccine could protect 79.22% of the subjects [17].
However, detailed vaccination information is not available and the
reported cases were not laboratory confirmed. Guo RN et al.
applied the Computer Assisted Telephone Interviewing System
(CATI) and found that the incidence of ILI among Guangzhou
residents in 2006 was estimated to be 22.9%, and the influenza
vaccination rate was 7.24%[18]. Unfortunately, in their study, the
authors did not report the vaccination rate among cases and the
healthy population by age and thus failed to determine the VE
against ILI in the city.
Our estimated VEs, based on healthy controls with no ARI
symptoms, were consistent with expectations of systematic trials
[19], but slightly different from reported findings in developed
countries [20,21], because partial vaccination showed weak
protection (about 32%) in children aged 24 o 59 months in our
study. Older children might have a better immune response to
partial vaccination than younger children. There are two studies
with findings similar to ours. A matched case-control study to
assess the influenza VE from 1999–2000 through 2006–2007 was
conducted in Olmsted County, MN, USA, which confirmed
strong protection in the fully vaccinated group against laboratory-
confirmed, medically attended influenza among children 6 to 59
months of age. The protective trend continued in the partially
vaccinated group (OR: 0.27, 95% CI, 0.07–0.97) [22]. Based on a
prospective case-control study in general practices and the
emergency department in Western Australia, Heath found that
the adjusted VE against laboratory-confirmed influenza among
children aged 6 to 59 months was 68%(95% CI, 26–86) [23].
There is one report that did not support the influenza vaccine’s
protective effect. Szilagyi et al. designed a case-cohort study to
estimate effectiveness of inactivated influenza vaccine in prevent-
ing inpatient and outpatient visits in 3 counties during the 2003–
2004 and 2004–2005 influenza seasons. However, based on 165
and 80 inpatient/ED and 74 and 95 outpatient influenza cases
during the 2003–2004 and 2004–2005 seasons, the authors could
Table 1. Seasonal Influenza Vaccine effectiveness in Children Aged 6 to 59 Months in 2009 and 2010, Guangzhou, China.
Vaccination Status Age 6–23 mo Age 24–59 mo Age 6–59 mo
Cases Controls
VE, Estimate
(95% CI),% Cases Controls
VE, Estimate




Fully vaccinated 55(7.78) 126(10.50) 61.01(44.06–72.83) 117(10.67) 262(21.83) 62.43(51.70–70.77) 172(9.52) 388(16.17) 51.79(41.31–60.40)
Partially vaccinated 15(2.12) 17(1.42) 8.52(231.84–36.53) 35(3.18) 86(7.17) 39.38(25.50–50.68) 50(2.77) 103(4.29) 32.43(19.24–43.47)
Unvaccinated 637(99.10) 1057(88.08) 1.00 947(86.17) 852(71.00) 1.00 1584(87.71) 1909(79.54) 1.00
Male 499(70.58) 600(50.00) 758(68.97) 600(50.00) 1257(69.60) 1200(50.00)
Age (yr) 1.3160.49 1.0060.82 3.6860.89 3.6760.47 2.7561.38 2.3361.49
Urban area 374(52.90) 600(50.00) 606(55.14) 600(50.00) 980(54.26) 1200(50.00)
2010
Fully vaccinated 17(5.66) 163(16.30) 73.37(54.72–84.34) 45(10.64) 201(17.63) 47.57(25.59–63.05) 62(8.58) 364(17.02) 57.78(43.61–68.39)
Partially vaccinated 9(3.00) 45(4.50) 23.86(210.53–47.55) 17(4.02) 97(8.51) 35.98(16.33–51.01) 26(3.60) 142(6.64) 32.51(16.10–45.72)
Unvaccinated 274(91.33) 837(83.70) 1.00 361(85.34) 842(73.86) 1.00 635(87.83) 1633(76.34) 1.00
Male 226(75.33) 519(51.95) 285(67.40) 570(50) 511(70.68) 1089(50.91)
Age (yr) 1.2960.49 1.1260.79 3.5060.90 3.6760.47 2.5861.33 2.4861.42
Urban area 148(49.33) 519(51.95) 193(45.63) 600(52.63) 341(47.16) 1119(52.31)
VE was adjusted for gender, age and area of residence (urban or rural area).
doi:10.1371/journal.pone.0030424.t001
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or outpatient visits in children younger than 5 years [20]. We
believe this may be because the sample is not representative.
Further study is needed during the coming years.
Selection bias in controls may be reduced by using standardized
computer methods to enroll healthy children, as opposed to
enrolling those with no confirmed viral infection among those with
ARI symptoms [23]. In this study, vaccination status was based on
electronic immunization records instead of parents’ or guardians’
recall, making it unlikely to be affected by recall bias. In addition,
the dates of disease onset and vaccination were electronically
recorded, which eliminated the possibility of including cases that
were out of temporal order with regard to the dates of disease
onset and vaccination [13].
There are other limitations to our study. As the 2009 pandemic
influenza (A) H1N1 caused significant concern in Guangzhou, a
large sample size was obtained during the 2009 study period for
children with ARI symptoms. As the concerns decreased, fewer
cases of ILI were reported to the surveillance sites in 2010, which
may have resulted in a sample of cases of ILI that is not
representative. We could not obtain the detailed information
needed to determine how well the circulating and vaccine strains
of influenza matched, and further study is needed.
We found full vaccination to be highly protective and partial
vaccination to be protective among older children. Influenza
vaccination in general should be encouraged, and full vaccination
should be particularly encouraged because its protective effect is
much stronger than that of partial vaccination.
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